Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Albireo Pharma, Inc. - Common Stock (NQ:ALBO)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Mar 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 44.10 (10)
Ask (Size) 44.30 (13)
Prev. Close 44.15
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 20,701,283
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings for Albireo Pharma
 
Via Benzinga
ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO
From Kahn Swick & Foti, LLC
Via Business Wire

Performance

More News

Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via GlobeNewswire
Cowen & Co. Downgrades Albireo Pharma: Here's What You Need To Know
Via Benzinga
Expert Ratings for Albireo Pharma
Via Benzinga
Looking Into Albireo Pharma's Return On Capital Employed
Via Benzinga
Why These Two Biotech Stocks Blasted Higher This Week
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 11, 2023
Via Benzinga
ALBIREO PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Albireo Pharma, Inc. - ALBO
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via GlobeNewswire
S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2023
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Surges Over 200 Points; Crude Oil Rises 2%
Via Benzinga
2 Tiny Nasdaq Stocks Making Major Merger Moves Monday
Via The Motley Fool
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
Via Benzinga
US Stocks Open Higher; Dow Rises 150 Points
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 9, 2023
Via Benzinga
ALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
Via Benzinga
Have A Look At William Blair's Top Biotech Picks For 2023
Via Benzinga

Frequently Asked Questions

Is Albireo Pharma, Inc. - Common Stock publicly traded?
Yes, Albireo Pharma, Inc. - Common Stock is publicly traded.
What exchange does Albireo Pharma, Inc. - Common Stock trade on?
Albireo Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Albireo Pharma, Inc. - Common Stock?
The ticker symbol for Albireo Pharma, Inc. - Common Stock is ALBO on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.